- Home
- GDST vs OMIC Comparison
GDST vs OMIC Comparison
Compare GDST & OMIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDST
- OMIC
- Stock Information
- Founded
- GDST 2020
- OMIC 2016
- Country
- GDST United States
- OMIC United States
- Employees
- GDST N/A
- OMIC N/A
- Industry
- GDST
- OMIC Medical/Dental Instruments
- Sector
- GDST
- OMIC Health Care
- Exchange
- GDST NYSE
- OMIC Nasdaq
- Market Cap
- GDST 38.7M
- OMIC 34.9M
- IPO Year
- GDST 2022
- OMIC 2021
- Fundamental
- Price
- GDST $11.20
- OMIC $21.88
- Analyst Decision
- GDST
- OMIC Hold
- Analyst Count
- GDST 0
- OMIC 2
- Target Price
- GDST N/A
- OMIC $10.75
- AVG Volume (30 Days)
- GDST 16.0
- OMIC 34.7K
- Earning Date
- GDST 01-01-0001
- OMIC 11-12-2024
- Dividend Yield
- GDST N/A
- OMIC N/A
- EPS Growth
- GDST 101.53
- OMIC N/A
- EPS
- GDST 0.22
- OMIC N/A
- Revenue
- GDST N/A
- OMIC $2,667,000.00
- Revenue This Year
- GDST N/A
- OMIC $10.41
- Revenue Next Year
- GDST N/A
- OMIC $222.15
- P/E Ratio
- GDST $51.83
- OMIC N/A
- Revenue Growth
- GDST N/A
- OMIC 2.77
- 52 Week Low
- GDST $10.47
- OMIC $5.34
- 52 Week High
- GDST $12.45
- OMIC $23.41
- Technical
- Relative Strength Index (RSI)
- GDST 14.61
- OMIC 66.05
- Support Level
- GDST $11.15
- OMIC $21.26
- Resistance Level
- GDST $11.26
- OMIC $22.14
- Average True Range (ATR)
- GDST 0.00
- OMIC 0.89
- MACD
- GDST -0.00
- OMIC -0.13
- Stochastic Oscillator
- GDST 0.00
- OMIC 35.71
About GDST GOLDENSTONE ACQUISITION LIMITED
Goldenstone Acquisition Ltd is a newly organized blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About OMIC Singular Genomics Systems Inc.
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.